Navigation Links
Study identifies possible new target for future brain cancer drugs
Date:2/27/2014

hese patients, so a PRMT5 inhibitor might be particularly important for these patients," says Kaur, who is specializes in glioblastoma research and is chief of Ohio State's Dardinger Laboratory of Neurosciences.

PRMT5 (protein arginine methyltransferase 5) is an enzyme that alters the structure of chromatin to suppress the transcription of genes and the production of proteins. To conduct their study, Kaur, Baiocchi and their colleagues used tumor tissue from patients, cell lines and an animal model. Key findings included:

  • PRMT5 is selectively over-expressed in glioblastoma and the degree of PRMT5 expression correlates with cell growth and patient survival.
  • In GBM patients, PRMT5 expression levels in tumor were significantly associated with lower overall survival;
  • Patients with high PRMT5 tumor expression had shorter overall survival (108 days) compared to patients with medium expression (277 days) and low expression (726 days).


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 The partners of Urgent Care ... present Dr. Alicia Almendral as their chief provider for ... of the newly opened facility’s plan to offer all ... treatments. , Dr. Almendral is a board certified physician ... and cosmetic enhancement techniques. Her areas of expertise include ...
(Date:5/28/2015)... Colorado (PRWEB) May 28, 2015 On ... The Longest Day®, a team event to honor the ... Held annually on summer solstice, the duration of this ... with the disease and their caregivers. Participants raise funds ... efforts of the Alzheimer’s Association. , Teams are encouraged ...
(Date:5/28/2015)... 2015 Dr. Jenyons’ Medical Weight ... deal to patients looking to undergo its advanced Micro-Needling ... patients will be able to get a single Micro-Needling ... $600. For a three-treatment package, which costs $1,800, the ... cost. , Dr. Juanita Jenyons, M.D., says Dr. Jenyons’ ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO ... in the role of president. , “ Bill Taaffe ... industry,” said Larry Flanagan, Medelis’ CEO and co-founder. “He will ... next phase of growth.” , Taaffe joined ICON’s U.S. ... employees to over 4,500 employees, achieving 12 consecutive years of ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Altima ... Stencils Device Library for documenting and diagramming data ... Stencils for the following product lines: , ... ASA 5500, Chatsworth Products N-Series TeraFrame Cabinet, Middle ... Corning Eclipse, Fore Systems ForeRunner, Marantz America MM ...
Breaking Medicine News(10 mins):Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 2Health News:Dr. Jenyons’ Medical Weight Loss & Rejuvenation Center Now Offering Skin Treatment Specials 3Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:NetZoom™ Visio® Stencil Library Updates for EMC, Cisco, and Chatsworth Products 2
... surgery, which is used to treat Parkinsons disease and ... potential to treat a variety of conditions. For example, ... cluster headaches and aggressiveness in humans, and stimulating this ... found that hypothalamic DBS performed in the treatment of ...
... the radiocarbon dating method and special proteins in the lens ... Aarhus can now establish, with relatively high precision, when a ... scientists who can use it to establish the date of ... consequences for health science research. The findings are published in ...
... preventable source of death and disability in the USA, contributing ... the health dangers, 1 in 8 American adults is ... scientists have known that most of the risk for habitual ... by genetics. This conclusion comes from the study of ...
... degree program addresses growing mental health workforce,crisis, ... the,growing mental health workforce crisis, California Institute of ... program in,Community Mental Health in fall 2008., ... Psychology with a,concentration in Community Mental Health, as ...
... A drug used to treat kidney cancer also targets a ... acute myeloid leukemia (AML), the most common and lethal form ... D. Anderson Cancer Center report in the Jan. 29 edition ... a Phase I clinical trial, the drug sorafenib reduced the ...
... Adjusted net income increases 84% to $250 million ... December 31, 2007 as,follows:, , (US$ in millions, except EPS) ... Periods ... Ended ...
Cached Medicine News:Health News:Deep brain stimulation may improve memory 2Health News:The eyes have it 2Health News:DNA (driver of nicotine addiction) 2Health News:California Institute of Integral Studies Launches Groundbreaking Community Mental Health Program 2Health News:California Institute of Integral Studies Launches Groundbreaking Community Mental Health Program 3Health News:Kidney cancer drug attacks a major type of acute myeloid leukemia 2Health News:Kidney cancer drug attacks a major type of acute myeloid leukemia 3Health News:Flextronics Announces Third Quarter Results 2Health News:Flextronics Announces Third Quarter Results 3Health News:Flextronics Announces Third Quarter Results 4Health News:Flextronics Announces Third Quarter Results 5Health News:Flextronics Announces Third Quarter Results 6Health News:Flextronics Announces Third Quarter Results 7Health News:Flextronics Announces Third Quarter Results 8Health News:Flextronics Announces Third Quarter Results 9Health News:Flextronics Announces Third Quarter Results 10Health News:Flextronics Announces Third Quarter Results 11Health News:Flextronics Announces Third Quarter Results 12Health News:Flextronics Announces Third Quarter Results 13Health News:Flextronics Announces Third Quarter Results 14Health News:Flextronics Announces Third Quarter Results 15Health News:Flextronics Announces Third Quarter Results 16Health News:Flextronics Announces Third Quarter Results 17Health News:Flextronics Announces Third Quarter Results 18Health News:Flextronics Announces Third Quarter Results 19
(Date:5/28/2015)... May 28, 2015   Mast Therapeutics, Inc. ... leveraging its molecular adhesion and sealant technology (MAST) ... disease, heart failure, and arterial disease, today announced ... Company,s Board of Directors. Mr. Lief made this ... given his role as President and Chief Executive ...
(Date:5/28/2015)... May 28, 2015  Shareholder rights law firm ... certain officers and directors of Eleven Biotherapeutics, Inc. (NASDAQGM: ... Biotherapeutics is a clinical-stage biopharmaceutical company that engages ... to treat eye diseases, primarily in ... View this press release on the law firm,s ...
(Date:5/28/2015)... 2015 The amount Americans spend on healthcare ... with growth of 8% will reach $608 billion by ... directly on expenditures, co-pays as part of office visits ... The publisher made its finding in its most recent ... United States . Information on ...
Breaking Medicine Technology:Mast Therapeutics Announces Change In Board Of Directors 2Mast Therapeutics Announces Change In Board Of Directors 3Mast Therapeutics Announces Change In Board Of Directors 4Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3
... 4 Thoratec Corporation (Nasdaq: THOR ), a world ... and restore failing hearts, said today that revenues for the ... of nine percent over revenues of $80.8 million in the ... reflect a 14 percent increase in revenues from the company,s ...
... YORK, Nov. 4 NeoStem, Inc. (NYSE Amex: ... has been named to the Company,s Board of Directors. ... operating global biotechnology businesses. , Serving as Executive Vice ... global commercial operations of Abraxis Bioscience, a global biotechnology ...
Cached Medicine Technology:Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 2Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 3Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 4Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 6Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 7Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 8Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 9Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 10Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 11Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 12Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 13Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 14Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 15Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 16Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 17Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 18Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 19NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations 2NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: